Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01460654 · ClinicalTrials.gov registry record · Phase 2
Testosterone and Alendronate in Hypogonadal Men
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT01460654: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT01460654 is a Phase 2 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01460654, a Phase 2 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
This study will investigate the hypothesis that the combination of testosterone replacement and alendronate will improve bone density and parameters of bone quality more than either medication alone in older men with low testosterone levels and low bone density.
Interventions
- DRUG Testosterone
- DRUG Alendronate
- DRUG Placebo Alendronate
- DRUG Placebo Testosterone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2011-10 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01460654
The ClinicalTrials.gov registry entry for NCT01460654 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Testosterone is the first listed.
NCT01460654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01460654 about?
NCT01460654 is a clinical study titled "Testosterone and Alendronate in Hypogonadal Men". This study will investigate the hypothesis that the combination of testosterone replacement and alendronate will improve bone density and parameters of bone quality more than either medication alone in older men with low testosterone levels and low bone density.
What is the current status of trial NCT01460654?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2011-10. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01460654?
The interventions under investigation include: Testosterone (DRUG), Alendronate (DRUG), Placebo Alendronate (DRUG), Placebo Testosterone (DRUG).
Who is sponsoring clinical trial NCT01460654?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.